Aim: In this study, we aimed to investigate the pharmacodynamic effects of rocuronium when dosed according to real or ideal body weights of morbidly obese patients and compare the results with normal body weight patients.Material and Methods: Sixteen morbidly obese patients (body mass index [BMI] >40 kg/m–2) and 8 patients with normal body weights (BMI
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aim: In this study, we aimed to investigate the pharmacodynamic effects of rocuronium when dosed according to real or ideal body weights of morbidly obese patients and compare the results with normal body weight patients.Material and Methods: Sixteen morbidly obese patients (body mass index [BMI] >40 kg/m–2) and 8 patients with normal body weights (BMI
📊
Key Findings & Data:Aim: In this study, we aimed to investigate the pharmacodynamic effects of rocuronium when dosed according to real or ideal body weights of morbidly obese patients and compare the results with normal body weight patients.Material and Methods: Sixteen morbidly obese patients (body mass index [BMI] >40 kg/m–2) and 8 patients with normal body weights (BMI
💡
Conclusion & Impact:Aim: In this study, we aimed to investigate the pharmacodynamic effects of rocuronium when dosed according to real or ideal body weights of morbidly obese patients and compare the results with normal body weight patients.Material and Methods: Sixteen morbidly obese patients (body mass index [BMI] >40 kg/m–2) and 8 patients with normal body weights (BMI
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Aim: In this study, we aimed to investigate the pharmacodynamic effects of rocuronium when dosed according to real or ideal body weights of morbidly obese patients and compare the results with normal body weight patients.Material and Methods: Sixteen morbidly obese patients (body mass index [BMI] >40 kg/m–2) and 8 patients with normal body weights (BMI
Özet
Amaç: Çalışmamızda, morbid obez hastalarda ideal veya gerçek vücut ağırlığına göre uygulanan rokuronyumun farmakodinamik etkisinin araştırılması ve obez olmayan hastalarla karşılaştırılması amaçlandı.Gereç ve Yöntem: Anestezi uygulaması sırasında 16 morbid obez (vücut kütle indeksi (VKİ) >40 kg m–2) ve 8 normal kilolu (VKİ
🔖
Cite This Article
BALCIOĞLU, S. T., ALPER, I., YEGÜL, İ., ARIKAN, N., ULUKAYA, S. (2022). The pharmacodynamic effects of rocuronium in morbidly obese patients. Türk Anestezi ve Reanimasyon Dergisi, Cilt: 37 - Sayı: 4, 234–239. https://ajindex.com/articles/619944
Kral JG. Morbid obesity and related health risks. Ann Intern Med 1985;103:1043-7
Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000;39:215-31
Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 1981;217:681-5
Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004;99:1086-9
Pühringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999;16:507-10
Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004;99:1090-4
Salihoğlu Z, Demiroluk Ş, Köse Y. Morbid obez hastalarda cisatarkuryumun nöromusküler iletime etkileri. Anestezi Dergisi 2002;10:247-50
Weinstein JA, Matteo RS, Ornstein E, et al. Pharmacodynamics of vecuronium and atracurium in the obese patient. Anesth Analg 1988;67:1149-53
Pühringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients. Eur J Anaesthesiol Suppl l995;11:107-10
Khuenl-Brady KS, Sparr H. Clinical pharmacokinetics of rocuronium bromide. Clin Pharmacokinet 1996;31:174-83.